Early Beleodaq win for Spectrum bodes well for Onxeo
This article was originally published in Scrip
Executive Summary
The FDA on 3 July surprised Spectrum Pharmaceuticals and its partner Topotarget – which is finalizing a merger with BioAlliance to form Onxeo – by granting approval of Beleodaq (belinostat) more than a month ahead of schedule as a treatment for patients with peripheral T-cell lymphoma (PTCL), a diverse group of rare and aggressive diseases, which account for up to 15% of all non-Hodgkin lymphomas.
You may also be interested in...
US FDA Biosimilars Staff Faces More Transition As Sue Lim Departs After Christl
Sue Lim, who serves as director of scientific review staff of the US FDA's Therapeutic Biologics and Biosimilars Staff, will be leaving the agency at the end of February to start an independent consulting firm.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.